Biotech Startups

Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse. The company has advanced two internally generated immunotherapies into clinical trials and maintains a strategic alliance with Gilead Sciences.

4 investors

Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases. Its lead candidate, TPM502, targets liver sinusoidal endothelial cells and is being developed for celiac disease, having completed a Phase 2a study.

4 investors

Transcera is a biotech company developing a new class of therapeutics that use lipid trafficking pathways to direct extracellular proteins into lysosomes for degradation, aimed at treating chronic diseases. Its platform combines a lysosome-targeting lipid, a chemical linker, and a peptide or protein binder to degrade soluble and membrane proteins across tissues.

4 investors

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research. The company serves cancer patients through drug discovery and development.

4 investors

Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases. Its lead investigational candidate, TTHX1114, is being studied in a Phase 2 trial for improving visual recovery after Descemet Stripping Only (DSO) procedures.

4 investors

Trestle Biotherapeutics develops bioengineered implantable tissues designed to treat end-stage renal disease, aiming to get patients off dialysis and eventually provide replacement organs. The company uses stem cell biology, biofabrication, and 3D bioprinting technologies to create functional kidney tissue for patients with kidney failure.

4 investors

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways. Its lead candidate, TRX-44, aims to treat fibrotic diseases affecting organs such as the lungs and kidneys regardless of cause.

4 investors

4 investors

Trilobio builds lab automation systems designed for biologists to conduct experiments reliably and accessibly. The company develops tools to reduce manual workflows and human error in biological research, serving researchers across academic and commercial labs.

4 investors

TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.

4 investors

Triplebar builds an AI platform for Genomic Design Automation (GDA), using microfluidics to generate large-scale biological datasets with matched genotype and phenotype at lower cost and faster than liquid handling robotics. It applies machine learning to biological data to support biotechnology research and product engineering.

4 investors

Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers. It focuses on oncology and immunotherapy drug development.

4 investors

Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment. The company applies T cell biology and targeted immunotherapy approaches to address oncology.

4 investors

Ukko develops immuno-therapeutics for life-threatening food allergies using a computational protein design platform. It applies AI and protein micro-engineering to create modified allergens that retrain the immune system to tolerate the allergen without triggering an allergic response.

4 investors

UBC provides biopharma companies with services in real-world evidence development, drug safety and risk management (including REMS), and patient access, affordability, and adherence support. Its work focuses on specialty therapies, helping sponsors demonstrate long-term product value and improve patient outcomes.

4 investors

UrbanKisaan develops machine learning models and hardware systems for accelerated plant breeding. The company creates foundation models that predict plant traits from genetic sequences and environmental data, paired with controlled-environment chambers that compress traditional multi-year breeding cycles into months by enabling rapid generations and continuous phenotype data collection.

4 investors

Valinor Discovery generates patient-derived datasets combining multi-omics and clinical data to enable machine learning applications in drug development. The company collects longitudinal data across molecular and imaging assays to create virtual patient profiles for pharmaceutical research.

4 investors

Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions. It serves patients with these diseases through its drug discovery and development work.

4 investors

Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.

4 investors

VedaBio develops a molecular detection platform using CRISPR technology that enables rapid, accurate detection of multiple biological targets without the need for amplification. The platform serves research, diagnostics, and industrial applications across multiple markets.

4 investors

Ventaris Surgical develops investigational medical devices that are currently under development and have not yet received FDA or other regulatory approval for commercial use.

4 investors

Verisian builds software for clinical research and public health authorities to analyze and monitor clinical trial data in real-time, improving decision-making and trial safety. The platform addresses limitations in traditional CDISC standardization by streamlining analysis and submission cycles.

4 investors

Vertoro is a bio-based chemicals company that converts woody and agricultural residues into green alternatives to fossil crude oil for use as platform products in materials, chemicals, and fuels. The company operates a scalable production platform validated at Technology Readiness Level 6 and serves industrial customers across oil, shipping, and chemical sectors seeking sustainable substitutes.

4 investors

Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease. Its pipeline includes neuropeptides and small molecules aimed at cognitive impairment, depression, anxiety, and inflammatory disease.

4 investors